Novo led a $112m Series B round in AvenCell.

Novo, a life science investor, led a $112m Series B round in AvenCell, a clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, with participation from F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYBC Ventures and Blackstone Life Sciences. "We are excited by the progress of our pipeline and believe our next-generation immunotherapies have the power to address significant unmet patient needs. AvenCell is working to transform the standard of care through switchable, adaptable and readily available cell therapy treatments that can better treat a wide range of difficult-to-treat cancer and autoimmune diseases. The support of Novo Holdings and this leading group of new investors will be integral to our ability to progress and bring these therapies to patients," Andrew Schiermeier, AvenCell Therapeutics Chief Executive Officer.